Cargando…
P357: DECITABINE CONSOLIDATION AFTER CD19/CD22 CAR-T THERAPY IS A NOVEL STRATEGY TO IMPROVE OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428363/ http://dx.doi.org/10.1097/01.HS9.0000968340.78094.c9 |
| _version_ | 1785090450966708224 |
|---|---|
| author | LI, Tingting Cui, Qingya Liu, Sining LI, Zheng Cui, Wei LI, Mengyun Zhu, Xiaming Kang, Liqing Yu, Lei Wu, Depei Tang, Xiaowen |
| author_facet | LI, Tingting Cui, Qingya Liu, Sining LI, Zheng Cui, Wei LI, Mengyun Zhu, Xiaming Kang, Liqing Yu, Lei Wu, Depei Tang, Xiaowen |
| author_sort | LI, Tingting |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428363 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104283632023-08-17 P357: DECITABINE CONSOLIDATION AFTER CD19/CD22 CAR-T THERAPY IS A NOVEL STRATEGY TO IMPROVE OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA LI, Tingting Cui, Qingya Liu, Sining LI, Zheng Cui, Wei LI, Mengyun Zhu, Xiaming Kang, Liqing Yu, Lei Wu, Depei Tang, Xiaowen Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428363/ http://dx.doi.org/10.1097/01.HS9.0000968340.78094.c9 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters LI, Tingting Cui, Qingya Liu, Sining LI, Zheng Cui, Wei LI, Mengyun Zhu, Xiaming Kang, Liqing Yu, Lei Wu, Depei Tang, Xiaowen P357: DECITABINE CONSOLIDATION AFTER CD19/CD22 CAR-T THERAPY IS A NOVEL STRATEGY TO IMPROVE OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA |
| title | P357: DECITABINE CONSOLIDATION AFTER CD19/CD22 CAR-T THERAPY IS A NOVEL STRATEGY TO IMPROVE OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA |
| title_full | P357: DECITABINE CONSOLIDATION AFTER CD19/CD22 CAR-T THERAPY IS A NOVEL STRATEGY TO IMPROVE OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA |
| title_fullStr | P357: DECITABINE CONSOLIDATION AFTER CD19/CD22 CAR-T THERAPY IS A NOVEL STRATEGY TO IMPROVE OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA |
| title_full_unstemmed | P357: DECITABINE CONSOLIDATION AFTER CD19/CD22 CAR-T THERAPY IS A NOVEL STRATEGY TO IMPROVE OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA |
| title_short | P357: DECITABINE CONSOLIDATION AFTER CD19/CD22 CAR-T THERAPY IS A NOVEL STRATEGY TO IMPROVE OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA |
| title_sort | p357: decitabine consolidation after cd19/cd22 car-t therapy is a novel strategy to improve outcomes in patients with relapsed or refractory b-cell acute lymphoblastic leukemia |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428363/ http://dx.doi.org/10.1097/01.HS9.0000968340.78094.c9 |
| work_keys_str_mv | AT litingting p357decitabineconsolidationaftercd19cd22carttherapyisanovelstrategytoimproveoutcomesinpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemia AT cuiqingya p357decitabineconsolidationaftercd19cd22carttherapyisanovelstrategytoimproveoutcomesinpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemia AT liusining p357decitabineconsolidationaftercd19cd22carttherapyisanovelstrategytoimproveoutcomesinpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemia AT lizheng p357decitabineconsolidationaftercd19cd22carttherapyisanovelstrategytoimproveoutcomesinpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemia AT cuiwei p357decitabineconsolidationaftercd19cd22carttherapyisanovelstrategytoimproveoutcomesinpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemia AT limengyun p357decitabineconsolidationaftercd19cd22carttherapyisanovelstrategytoimproveoutcomesinpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemia AT zhuxiaming p357decitabineconsolidationaftercd19cd22carttherapyisanovelstrategytoimproveoutcomesinpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemia AT kangliqing p357decitabineconsolidationaftercd19cd22carttherapyisanovelstrategytoimproveoutcomesinpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemia AT yulei p357decitabineconsolidationaftercd19cd22carttherapyisanovelstrategytoimproveoutcomesinpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemia AT wudepei p357decitabineconsolidationaftercd19cd22carttherapyisanovelstrategytoimproveoutcomesinpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemia AT tangxiaowen p357decitabineconsolidationaftercd19cd22carttherapyisanovelstrategytoimproveoutcomesinpatientswithrelapsedorrefractorybcellacutelymphoblasticleukemia |